| abstract |
the present application relates to compounds of formula (i ') or formula (i), such as formula (ia), and their pharmaceutical compositions / preparations. this application also relates to methods of treatment or prevention of neurodegenerative disorders, such as alzheimer's disease (da), parkinson's disease (dp), huntington's disease (hd) and other diseases with cag triplet repeat (or polyglutamine), amyotrophic lateral sclerosis (her; lou gehrig's disease), diffuse lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (in), frontotemporal dementia, friedreich's ataxia, acute head injury and epilepsy (repression of activation of microglia). |